{
    "hands_on_practices": [
        {
            "introduction": "The origin of endometriosis is often linked to Sampson's theory of retrograde menstruation, where endometrial tissue flows backward into the pelvis. However, since this occurs in most menstruating individuals, it cannot be the sole cause. This practice problem uses a simplified probabilistic model to explore the crucial role of the immune system in clearing this ectopic tissue, demonstrating why immune evasion is a key step in the disease's pathophysiology. ",
            "id": "4785179",
            "problem": "Consider the pathophysiology of endometriosis, in which ectopic endometrial tissue implants are hypothesized to originate via retrograde menstruation and persist only if they evade immune clearance. Empirical observations indicate that retrograde menstruation is present in a large majority of menstruating individuals, whereas the disease prevalence remains substantially lower. Assume the following simplified, coarse-grained probabilistic model at the level of an individual:\n\n- Let $R$ be the event that retrograde menstruation occurs in the individual. The observed proportion is $P(R)=0.9$.\n- Let $I$ be the event that the immune system successfully clears the refluxed endometrial fragments such that implantation fails. Model immune clearance as a Bernoulli event with success probability $P(I)=p$, where $p$ is an unknown parameter representing immune clearance efficiency.\n- Let $D$ be the event that endometriosis develops. For this model, disease requires both the occurrence of retrograde menstruation and failure of immune clearance. Assume statistical independence between $R$ and $I$ at this coarse-grained level.\n- The observed disease prevalence is $P(D)=0.1$.\n\nStarting from the multiplication rule of probability for independent events and the definition that disease occurs if and only if retrograde menstruation occurs and immune clearance fails, derive an expression for the immune clearance efficiency parameter $p$ that reconciles the above observations. Compute its value using the given numerical proportions. Express the final answer as an exact fraction with no rounding and no units.",
            "solution": "The problem presents a simplified probabilistic model for the pathophysiology of endometriosis and asks for the derivation of the immune clearance efficiency parameter, $p$. The validation process confirms that the problem is scientifically grounded, well-posed, and objective. It provides a self-contained and consistent set of definitions and data, allowing for a unique solution.\n\nThe given parameters are:\n- $R$: The event of retrograde menstruation. The probability is given as $P(R) = 0.9$.\n- $I$: The event of successful immune clearance of refluxed endometrial fragments. The probability, representing the immune clearance efficiency, is $P(I) = p$.\n- $D$: The event that endometriosis develops. The prevalence is given as $P(D) = 0.1$.\n\nThe problem defines the condition for the development of endometriosis ($D$) as the co-occurrence of two events: retrograde menstruation ($R$) and the *failure* of immune clearance. The failure of immune clearance is the complement of the event $I$, denoted as $I^c$. The probability of immune clearance failure is therefore:\n$$P(I^c) = 1 - P(I) = 1 - p$$\n\nThe condition for disease development can be expressed as the intersection of events $R$ and $I^c$:\n$$D = R \\cap I^c$$\n\nThe problem states that the events $R$ and $I$ are to be considered statistically independent. A property of statistical independence is that if two events are independent, then their complements are also independent of each other, and each event is independent of the other's complement. Therefore, $R$ and $I^c$ are statistically independent.\n\nAccording to the multiplication rule for independent events, the probability of their intersection is the product of their individual probabilities:\n$$P(D) = P(R \\cap I^c) = P(R) \\times P(I^c)$$\n\nWe are given the numerical values for $P(D)$ and $P(R)$. It is convenient to express these decimal values as exact fractions:\n$P(D) = 0.1 = \\frac{1}{10}$\n$P(R) = 0.9 = \\frac{9}{10}$\n\nSubstituting these values and the expression for $P(I^c)$ into the probability equation yields:\n$$\\frac{1}{10} = \\frac{9}{10} \\times (1 - p)$$\n\nOur objective is to solve this equation for the parameter $p$. First, we can divide both sides of the equation by $\\frac{9}{10}$:\n$$\\frac{\\frac{1}{10}}{\\frac{9}{10}} = 1 - p$$\n$$\\frac{1}{9} = 1 - p$$\n\nNow, we rearrange the equation to isolate $p$:\n$$p = 1 - \\frac{1}{9}$$\n\nTo compute the final value, we find a common denominator:\n$$p = \\frac{9}{9} - \\frac{1}{9} = \\frac{8}{9}$$\n\nThus, the immune clearance efficiency parameter $p$ that reconciles the high incidence of retrograde menstruation with the lower prevalence of endometriosis, within this simplified model, is $\\frac{8}{9}$. This result implies that the immune system is approximately $88.9\\%$ effective at clearing the ectopic tissue, and disease develops in the fraction of cases where both retrograde menstruation occurs and this immune surveillance fails.",
            "answer": "$$\\boxed{\\frac{8}{9}}$$"
        },
        {
            "introduction": "Non-invasive diagnosis of endometriosis remains a major clinical challenge, with biomarkers like CA-125 showing limited utility. This exercise demonstrates how the performance of a diagnostic test is evaluated in a real-world clinical scenario. By applying Bayes' theorem to calculate the positive and negative predictive values, you will see how a test's usefulness depends critically on disease prevalence, a core concept in clinical epidemiology. ",
            "id": "4785220",
            "problem": "A cohort of reproductive-age individuals with pelvic pain and suspected endometriosis is evaluated using serum cancer antigen 125 (CA-125) at a selected threshold. In this pathophysiological context, ectopic endometrial tissue can drive peritoneal inflammation and stimulate mesothelial and ovarian expression of CA-125, yielding a diagnostic test with the following operating characteristics in this symptomatic population: sensitivity $0.50$, specificity $0.80$, and disease prevalence $0.10$.\n\nStarting only from the core definitions of sensitivity, specificity, and prevalence, and the application of Bayes' theorem to conditional probabilities, compute the positive predictive value (probability of disease given a positive test) and the negative predictive value (probability of no disease given a negative test) of CA-125 in this population. Report both values as decimals, and round your answers to four significant figures. No additional interpretation is required; provide only the numerical results.",
            "solution": "The problem requires the calculation of the positive predictive value (PPV) and the negative predictive value (NPV) for a diagnostic test, given its sensitivity, specificity, and the prevalence of the disease in the population. The solution will proceed from the fundamental definitions of these quantities and the application of Bayes' theorem.\n\nLet $D$ be the event that an individual has the disease (endometriosis), and let $D^c$ be the complementary event that the individual does not have the disease. Let $T^+$ denote a positive test result, and $T^-$ denote a negative test result.\n\nThe givens from the problem statement can be expressed in terms of conditional probabilities:\nThe prevalence of the disease is the prior probability of an individual having the disease, $P(D)$.\n$$P(D) = 0.10$$\nThe probability of an individual not having the disease is:\n$$P(D^c) = 1 - P(D) = 1 - 0.10 = 0.90$$\nSensitivity is the probability of a positive test given that the individual has the disease, $P(T^+|D)$.\n$$P(T^+|D) = 0.50$$\nSpecificity is the probability of a negative test given that the individual does not have the disease, $P(T^-|D^c)$.\n$$P(T^-|D^c) = 0.80$$\nFrom these definitions, we can derive the probabilities of the complementary conditional events:\nThe probability of a false negative (a negative test given disease) is:\n$$P(T^-|D) = 1 - P(T^+|D) = 1 - 0.50 = 0.50$$\nThe probability of a false positive (a positive test given no disease) is:\n$$P(T^+|D^c) = 1 - P(T^-|D^c) = 1 - 0.80 = 0.20$$\nThe first quantity to compute is the Positive Predictive Value (PPV), which is the probability that an individual has the disease given a positive test result, $P(D|T^+)$. Using Bayes' theorem:\n$$P(D|T^+) = \\frac{P(T^+|D) P(D)}{P(T^+)}$$\nThe denominator, $P(T^+)$, is the total probability of a positive test. It can be found using the law of total probability:\n$$P(T^+) = P(T^+|D)P(D) + P(T^+|D^c)P(D^c)$$\nSubstituting the known values:\n$$P(T^+) = (0.50)(0.10) + (0.20)(0.90) = 0.05 + 0.18 = 0.23$$\nNow, we can compute the PPV:\n$$PPV = P(D|T^+) = \\frac{(0.50)(0.10)}{0.23} = \\frac{0.05}{0.23} \\approx 0.217391304...$$\nRounding to four significant figures, the PPV is $0.2174$.\n\nThe second quantity to compute is the Negative Predictive Value (NPV), which is the probability that an individual does not have the disease given a negative test result, $P(D^c|T^-)$. Using Bayes' theorem:\n$$P(D^c|T^-) = \\frac{P(T^-|D^c) P(D^c)}{P(T^-)}$$\nThe denominator, $P(T^-)$, is the total probability of a negative test. It can be found either by the law of total probability or as the complement of $P(T^+)$.\nUsing the law of total probability:\n$$P(T^-) = P(T^-|D)P(D) + P(T^-|D^c)P(D^c)$$\n$$P(T^-) = (0.50)(0.10) + (0.80)(0.90) = 0.05 + 0.72 = 0.77$$\nAlternatively, $P(T^-) = 1 - P(T^+) = 1 - 0.23 = 0.77$. The results are consistent.\nNow, we can compute the NPV:\n$$NPV = P(D^c|T^-) = \\frac{(0.80)(0.90)}{0.77} = \\frac{0.72}{0.77} \\approx 0.935064935...$$\nRounding to four significant figures, the NPV is $0.9351$.\n\nThe computed values are PPV $\\approx 0.2174$ and NPV $\\approx 0.9351$.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.2174 & 0.9351\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "Managing endometriosis often involves hormonal therapies that suppress estrogen, which effectively treats the disease but can lead to significant side effects like bone loss. This practice problem models the physiological consequences of such treatment, asking you to calculate the cumulative bone mineral density loss and determine a therapeutic threshold for \"add-back\" estrogen. This exercise provides quantitative insight into the critical balance between treatment efficacy and mitigating adverse effects in chronic disease management. ",
            "id": "4785152",
            "problem": "A patient with endometriosis is treated with a gonadotropin-releasing hormone (GnRH) agonist, producing sustained hypoestrogenism with estradiol below $30\\,\\mathrm{pg/mL}$. In bone physiology, estrogen restrains osteoclast-mediated resorption by modulating receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG), such that hypoestrogenism increases net resorption. Assume the following simplified, scientifically plausible model consistent with these principles.\n\n1. When estradiol is fully suppressed below $30\\,\\mathrm{pg/mL}$, the net fractional bone mineral density (BMD) loss rate per month is $r=0.01$ (that is, a multiplicative monthly change on BMD of $1-r$).\n2. Let baseline BMD at $t=0$ be $B_0$. The discrete-time evolution over months is $B_{n+1}=(1-r)B_n$.\n3. To explore add-back therapy, let $E$ denote estradiol concentration. Assume net monthly fractional loss is governed by a dose-response $r(E)=k\\left(1-\\frac{E}{E^{\\ast}}\\right)$ for $E\\leq E^{\\ast}$, and $r(E)=0$ for $E\\geq E^{\\ast}$, where $E^{\\ast}=60\\,\\mathrm{pg/mL}$ is an approximate set-point at which net bone balance is neutral under normal remodeling. Calibrate $k$ using the empirical datum that $r(30\\,\\mathrm{pg/mL})=0.01$ under GnRH agonist-induced suppression.\n\nTasks:\n- Using the multiplicative model above, compute the cumulative BMD loss over $6$ months of full suppression (estradiol below $30\\,\\mathrm{pg/mL}$). Report the cumulative loss as a decimal fraction.\n- Using the calibrated $r(E)$, determine the minimal estradiol concentration $E_{\\min}$ (in $\\mathrm{pg/mL}$) required by add-back therapy to ensure the monthly loss rate satisfies $r(E)\\leq 0.0025$.\n\nRound both numerical results to four significant figures. Express the final estradiol concentration in $\\mathrm{pg/mL}$ and the cumulative loss as a unitless decimal fraction (do not use the percent sign).",
            "solution": "The problem is deemed valid. Its premises are scientifically grounded in the pathophysiology of hypoestrogenism-induced bone loss, a known side effect of gonadotropin-releasing hormone (GnRH) agonist therapy. The problem is well-posed, providing a self-contained, consistent, and formalizable mathematical model with all necessary data for its solution. The language is objective and precise.\n\nThe solution is divided into two parts, corresponding to the two tasks.\n\nFirst, we compute the cumulative bone mineral density (BMD) loss over $6$ months of full suppression.\nThe problem states that for full suppression (estradiol below $30\\,\\mathrm{pg/mL}$), the net fractional BMD loss rate per month is $r=0.01$. The discrete-time model for BMD, $B_n$, at month $n$ is given by $B_{n+1}=(1-r)B_n$, where $B_0$ is the baseline BMD at time $t=0$. This is a geometric progression, and the solution after $n$ months is $B_n = B_0(1-r)^n$.\nFor a period of $n=6$ months, the BMD is $B_6 = B_0(1-r)^6$.\nThe cumulative fractional loss, $L$, is the total loss relative to the baseline:\n$$L = \\frac{B_0 - B_6}{B_0} = 1 - \\frac{B_6}{B_0}$$\nSubstituting the expression for $B_6$:\n$$L = 1 - \\frac{B_0(1-r)^6}{B_0} = 1 - (1-r)^6$$\nWith the given loss rate $r=0.01$, the cumulative loss is:\n$$L = 1 - (1-0.01)^6 = 1 - (0.99)^6$$\nCalculating the numerical value:\n$$L = 1 - 0.941480149... = 0.058519851...$$\nRounding to four significant figures as requested, the cumulative loss is $0.05852$.\n\nSecond, we determine the minimal estradiol concentration, $E_{\\min}$, required for add-back therapy.\nThe net monthly fractional loss is given by the dose-response function $r(E)=k\\left(1-\\frac{E}{E^{\\ast}}\\right)$ for $E \\leq E^{\\ast}$, where $E^{\\ast}=60\\,\\mathrm{pg/mL}$. The model is calibrated using the empirical datum that $r(30\\,\\mathrm{pg/mL})=0.01$.\nWe substitute these values into the function to find the constant $k$:\n$$0.01 = k\\left(1-\\frac{30}{60}\\right)$$\n$$0.01 = k(1-0.5)$$\n$$0.01 = 0.5k$$\n$$k = \\frac{0.01}{0.5} = 0.02$$\nThe calibrated loss rate function is thus:\n$$r(E) = 0.02\\left(1 - \\frac{E}{60}\\right)$$\nThis formula is valid for $E \\leq 60\\,\\mathrm{pg/mL}$. We are asked to find the minimal concentration $E_{\\min}$ such that the monthly loss rate $r(E)$ is at most $0.0025$. This gives the inequality:\n$$r(E) \\leq 0.0025$$\n$$0.02\\left(1 - \\frac{E}{60}\\right) \\leq 0.0025$$\nWe solve this inequality for $E$:\n$$1 - \\frac{E}{60} \\leq \\frac{0.0025}{0.02}$$\n$$1 - \\frac{E}{60} \\leq 0.125$$\nTo isolate $E$, we rearrange the terms. Since $r(E)$ is a decreasing function of $E$, a lower loss rate requires a higher estradiol level.\n$$1 - 0.125 \\leq \\frac{E}{60}$$\n$$0.875 \\leq \\frac{E}{60}$$\n$$E \\geq 60 \\times 0.875$$\n$$E \\geq 52.5$$\nThe condition $r(E) \\leq 0.0025$ is satisfied for all estradiol concentrations $E \\geq 52.5\\,\\mathrm{pg/mL}$. The minimal concentration, $E_{\\min}$, is therefore $52.5\\,\\mathrm{pg/mL}$. This value is less than $E^{\\ast}=60\\,\\mathrm{pg/mL}$, confirming the use of the given formula for $r(E)$ is appropriate.\nAs required, this result must be reported to four significant figures, which is $52.50$.",
            "answer": "$$\\boxed{\\begin{pmatrix} 0.05852 & 52.50 \\end{pmatrix}}$$"
        }
    ]
}